

Bridging Gaps in Glaucoma Care With Supraciliary MIGS



On MIGS Unplugged, H. George Tanaka, MD, sits down with hosts Igbal Ike K. Ahmed. MD. FRCSC, and Arsham Shevbani, MD. to explain how supraciliary MIGS procedures can fill a niche in glaucoma patient care.



Commenting on the use of AlloFlo (lantrek) scleral spacers, Dr. Tanaka highlights the advantages of biocompatibility and shares insights into the best applications of this technology. The surgeons also review patient selection, clinical results, and how the risks and benefits of AlloFlo compare to those of other MIGS procedures.



Meeting Updates

Glaucoma Research Foundation New Horizons Forum

January 30; San Francisco

AGS Annual Meeting 2026

February 19-22; Rancho Mirage, California

AECOS Winter Symposium

February 22-25; Aspen, Colorado

ASCRS Annual Meeting 2026

April 10-13; Washington, DC

YoungMD Connect Live 2026

May 15-17; Austin, Texas

17th EGS Congress

May 30-June 2; Brussels

AECOS European Symposium June 11-14; Madrid

AECOS Summer Symposium

July 9-12; Deer Valley, Utah

ESCRS 2026 Annual Meeting September 11–15; London

AAO 2026 Annual Meeting October 9-12; New Orleans

Interventional Glaucoma Consortium 2026

November 13-15; Salt Lake City

IGC Fellows Program 2026

November 13-15; Salt Lake City









Reducing the Medication Burden for an Unhappy Patient

On Survey Says, a special edition of GT: The Podcast, guests Emily Schehlein, MD, and H. George Tanaka, MD, join host I. Paul Singh, MD, to review a case from his practice involving a patient with glaucoma and a history of selective laser trabeculoplasty and MIGS. Although the patient's IOP is at target, she is unhappy with her topical medication regimen. The group discusses the importance of quality of life and weighs possible next steps, including sustained drug delivery, repeat laser therapy, surgery, or continuing as is. Later, the guests find out what Dr. Singh did, and they compare their opinions with the results of a social media poll of GT's audience.

iDose TR: Patient Selection, Procedure Pearls, and Clinical Benefits



On Glaucoma Case Files, Rachel G. Simpson, MD, and Roya Garakani, DO, discuss the role of the iDose TR (Glaukos) procedural pharmaceutical and offer pearls for patient selection and implantation. Dr. Simpson explains how



sustained drug delivery options can benefit patients whose medication adherence is poor and minimize ocular surface side effects observed with topical drops. She comments on the use of iDose as a standalone intervention or in combination with surgery.